Aratana Therapeutics, a company developing innovative medicines for domestic animals, has raised a $12 million Series C round to fund the expansion of its pipeline of products. To date, the company has raised $47 million from investors including Avalon Ventures, Cultivian Ventures, Ewing Marion Kauffman Foundation, Kansas Bioscience Authority, MPM Capital, RaQualia Pharma and Sandbox Industries. In a press release, Dr. Steven St. Peter, the company’s president and CEO stated: “As we focus on advancing our current development pipeline toward approval and commercialization, we will use funds from this round to add to our portfolio of animal health products, ensuring Aratana’s future growth.”
